SOX18在前列腺癌中的表达及与患者远期预后的关系

doi:10.3969/j.issn.1671-7171.2020.10.021

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the expression of sex-determining region Y-box protein 18 (SOX18) in prostate cancer and its relationship with long-term prognosis. 【Methods】 A total of 140 patients with prostate cancer treated in our hospital from January 2012 to March 2017 were selected as the prostate cancer group, and 112 patients with benign prostatic hyperplasia were selected as the control group. The expression of SOX18 was detected by immunohistochemical staining, and the prognosis of patients was followed up. 【Results】 The positive expression rate of SOX18 in prostate cancer group was 70.00% (98/140), which was significantly higher than that in control group 40.18% (45/112). The difference was statistically significant (P<0.05). The positive expression rates of SOX18 in patients with TNM stage Ⅲ-Ⅳ, pathological grade G₃-G₄, PSA level > 20 ng/mL and Gleason score≥ 8 were 88.24%, 83.05%, 88.89% and 80.49%, respectively, which were significantly higher than those in patients with stage Ⅰ-Ⅱ, G₁-G₂, prostate specific antigen (PSA)≤20 ng/mL and Gleason score ≤7 (P<0.05). The median overall survival time of SOX18 positive patients was 50 months, which was significantly shorter than that of SOX18 negative patients (70 months); the difference was statistically significant (P<0.05). COX regression analysis showed that TNM stage, Gleason score and SOX18 expression were the prognostic factors of prostate cancer patients (HR=2.748,2.392 and 1.426, P<0.05). 【Conclusion】 The expression of SOX18 in prostate cancer is significantly up-regulated, which are related to clinical stage, pathological grade, PSA and Gleason, and also affect the prognosis of patients.

Key words： Prostatic Neoplasms/PA SOXF Transcription Factors Prognosis

Received: 13 May 2020

PACS:

R737.25

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Xue-wei
	YUAN Shuang
	SU Wan-yun
	et al

Cite this article:

XU Xue-wei,YUAN Shuang,SU Wan-yun, et al. SOX18 Expression with Patients' Long-term Prognosis in Prostate Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(10): 1511-1513.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.10.021 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I10/1511

[1] 丁宁,张志辉,陈伟,等.前列腺癌患者血清 miR-152、miR-32表达及其意义[J].医学临床研究, 2020, 37(6):840-842.
[2] 史涛,杭震宇,沈露明.LIMK1和 Cofilin 蛋白在前列腺癌组织中的表达及其临床意义[J].医学临床研究, 2020,37(4):525-527.
[3] 周文浩, 龚志勇, 廖波, 等. 前列腺癌主动监测期间组织ERG蛋白表达与肿瘤进展的关系[J].西部医学, 2018, 30(12):115-118+123.
[4] 周毅, 姚远, 杨剑文, 等. 上皮-间质转化调控蛋白在前列腺癌侵袭、转移中的作用及其临床预后诊断价值[J].华中科技大学学报(医学版), 2017, 46(4):397-403.
[5] 郝利娜,陈珂,鲁显福,等.脑电双频指数联合肌松监测在机器人辅助腹腔镜前列腺癌根治术老年患者中的应用[J].临床麻醉学杂志,2017,33(3):248-251.
[6] Buyyounouski MK, Choyke PL, Mckenney JK, et al. Prostate cancer-major changes in the American Joint Committee on cancer eighth edition cancer staging manual[J].Cancer J Clin,2017, 67(6):472-474.
[7] Griffin T. Abiraterone in metastatic prostate cancer[J].N Engl J Med,2017, 377(17):1694-1696.
[8] Long MD, Smiraglia DJ, Campbell MJ. The genomic impact of DNA CPG methylation on gene expression; relationships in prostate cancer[J].Biomolecules,2017, 7(1):15-16.
[9] Chung AG, Khalvati F, Shafiee MJ, et al. Prostate cancer detection via a quantitative radiomics-driven conditional random field framework[J].IEEE Access,2017, 3(3):2531-2541.
[10] Nguyen HM, Vessella RL, Morrissey C, et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics[J].Prostate,2017, 77(6):654-655.
[11] James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy[J].N Engl J Med,2017, 377(4):338-340.
[12] Zhang J, Cunningham JJ, Brown JS, et al. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer: a pilot multidisciplinary study[J].Cancer Res,2017, 77(13):5562.
[13] Dai J, Lu Y, Roca H, et al. Immune mediators in the tumor microenvironment of prostate cancer[J].Chin J Cancer,2017, 36(3):131-138.
[14] Munkley J, Livermore K, Rajan P, et al. RNA splicing and splicing regulator changes in prostate cancer pathology[J].Hum Genet,2017, 136(9):1143-1154.
[15] Schmidt JA, Fensom GK, Rinaldi S， et al. Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition[J].BMC Med,2017, 15(1):122-124.